In this interview we discuss prognostic models that may be able to predict disease progression in patients with chronic lymphocytic leukemia treated with the targeted agent ibrutinib.
Inhye E. Ahn, MD
Advertisement
Articles by Inhye E. Ahn, MD
Advertisement
Latest Updated Articles
Predicting Disease Progression in CLL Patients on IbrutinibPublished: December 3rd 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
3
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
4
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
5
